Veru Management
Management Kriterienprüfungen 3/4
Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.
Wichtige Informationen
Mitch Steiner
Geschäftsführender
US$4.7m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 18.4% |
| Amtszeit als Geschäftsführer | 8yrs |
| Eigentum des Geschäftsführers | 4.8% |
| Durchschnittliche Amtszeit des Managements | 6.1yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 3.8yrs |
Jüngste Management Updates
Recent updates
Is Veru (NASDAQ:VERU) A Risky Investment?
Aug 07
What Veru Inc.'s (NASDAQ:VERU) 28% Share Price Gain Is Not Telling You
Jul 17Veru Inc.'s (NASDAQ:VERU) 35% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
May 31The Price Is Right For Veru Inc. (NASDAQ:VERU) Even After Diving 52%
Jan 09Revenue Downgrade: Here's What Analysts Forecast For Veru Inc. (NASDAQ:VERU)
Aug 16Veru Inc.'s (NASDAQ:VERU) Stock Retreats 38% But Revenues Haven't Escaped The Attention Of Investors
Apr 17Veru Inc.'s (NASDAQ:VERU) Intrinsic Value Is Potentially 99% Above Its Share Price
Feb 14Veru (NASDAQ:VERU) Has Debt But No Earnings; Should You Worry?
Jan 13Analysts Just Shaved Their Veru Inc. (NASDAQ:VERU) Forecasts Dramatically
Nov 13Veru Inc.: Safer Bet Is To Wait For The AdComm Verdict
Oct 17Is Veru (NASDAQ:VERU) Weighed On By Its Debt Load?
Sep 26Veru FDA AdCom meeting for COVID-19 therapy postponed
Sep 19Veru: A Good Combination Of A Stable Business And Growth Opportunities
Sep 13Veru surges 11% as FDA sets AdCom meeting to review COVID-19 therapy
Sep 07Veru sheds 13% to end rally as director sells shares
Aug 18Veru Q3 2022 Earnings Preview
Aug 10Veru updated analysis on COVID treatment sabizabulin will lead to EUA - Oppenheimer
Aug 03Veru eligible for expedited review in U.K. for COVID-19 therapy
Jul 25Veru: The Signs Seem To Point To An EUA For Sabizabulin
Jul 13Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$37m |
| Mar 31 2024 | n/a | n/a | -US$39m |
| Dec 31 2023 | n/a | n/a | -US$63m |
| Sep 30 2023 | US$5m | US$866k | -US$93m |
| Jun 30 2023 | n/a | n/a | -US$126m |
| Mar 31 2023 | n/a | n/a | -US$136m |
| Dec 31 2022 | n/a | n/a | -US$116m |
| Sep 30 2022 | US$6m | US$761k | -US$84m |
| Jun 30 2022 | n/a | n/a | -US$47m |
| Mar 31 2022 | n/a | n/a | -US$28m |
| Dec 31 2021 | n/a | n/a | -US$16m |
| Sep 30 2021 | US$2m | US$618k | US$7m |
| Jun 30 2021 | n/a | n/a | -US$144k |
| Mar 31 2021 | n/a | n/a | -US$476k |
| Dec 31 2020 | n/a | n/a | US$2m |
| Sep 30 2020 | US$1m | US$502k | -US$19m |
| Jun 30 2020 | n/a | n/a | -US$10m |
| Mar 31 2020 | n/a | n/a | -US$10m |
| Dec 31 2019 | n/a | n/a | -US$13m |
| Sep 30 2019 | US$800k | US$392k | -US$12m |
| Jun 30 2019 | n/a | n/a | -US$17m |
| Mar 31 2019 | n/a | n/a | -US$22m |
| Dec 31 2018 | n/a | n/a | -US$22m |
| Sep 30 2018 | US$740k | US$383k | -US$24m |
Vergütung im Vergleich zum Markt: MitchDie Gesamtvergütung ($USD4.71M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD673.68K).
Entschädigung vs. Einkommen: MitchDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
Geschäftsführer
Mitch Steiner (63 yo)
8yrs
Amtszeit
US$4,714,041
Vergütung
Dr. Mitchell S. Steiner, also known as Mitch, M.D., F.A.C.S, has been the Chief Executive Officer, President and Director at Veru Inc. (formerly known as The Female Health Company) since October 31, 2016 &...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Chairman | 8yrs | US$4.71m | 4.84% $ 5.3m | |
| Vice Chairman & Chief Corporate Officer | 8yrs | keine Daten | 5.47% $ 6.0m | |
| CFO & Chief Administrative Officer | 6.8yrs | US$1.55m | 0.066% $ 72.5k | |
| Chief Scientific Officer | 6.1yrs | US$1.69m | 0.0034% $ 3.8k | |
| Executive Director of Investor Relations & Corporate Communications | 5.5yrs | keine Daten | keine Daten | |
| Executive VP | 3.6yrs | keine Daten | keine Daten | |
| Executive Vice President of Corporate Development | 7.8yrs | keine Daten | keine Daten | |
| Executive Vice President of FC2 Global Operations | no data | US$193.01k | keine Daten | |
| Executive VP & Deputy General Counsel | 3.8yrs | keine Daten | keine Daten | |
| Executive Vice President of Global Clinical Operations | 6.5yrs | keine Daten | keine Daten | |
| Executive Vice President of Quality & Regulatory Affairs | 5.7yrs | keine Daten | keine Daten | |
| Executive VP and GM of UK | 2.2yrs | keine Daten | keine Daten |
6.1yrs
Durchschnittliche Betriebszugehörigkeit
62.5yo
Durchschnittliches Alter
Erfahrenes Management: VERUDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (5.8 ).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Chairman | 8yrs | US$4.71m | 4.84% $ 5.3m | |
| Vice Chairman & Chief Corporate Officer | 8yrs | keine Daten | 5.47% $ 6.0m | |
| Chief Medical Advisor & Member of the Scientific Advisory | less than a year | keine Daten | keine Daten | |
| Chairman of Scientific Advisory Board | 1.8yrs | keine Daten | keine Daten | |
| Board Observer | 8yrs | keine Daten | keine Daten | |
| Member of the Scientific Advisory Board | 1.3yrs | keine Daten | keine Daten | |
| Independent Director | 6.6yrs | US$875.93k | 0.068% $ 75.4k | |
| Independent Director | 3.4yrs | US$835.75k | 0.0067% $ 7.4k | |
| Member of Scientific Advisory Board | less than a year | keine Daten | keine Daten | |
| Independent Director | 8yrs | US$795.57k | 0% $ 0 | |
| Independent Director | 4.2yrs | US$755.39k | 0.010% $ 11.1k | |
| Member of the Scientific Advisory Board | 1.3yrs | keine Daten | keine Daten |
3.8yrs
Durchschnittliche Betriebszugehörigkeit
66yo
Durchschnittliches Alter
Erfahrener Vorstand: VERUDie Vorstandsmitglieder gelten als erfahren (3.5 Jahre durchschnittliche Amtszeit).